Rheumatology in Practice: Assessing Disease Activity in Psoriatic Arthritis
Source: Rheumatology in Practice

Module

In this resource, Vinod Chandran, MBBS, MD, DM, PhD,reviews the current approach to diagnosis, comprehensive disease assessment, and treatment of PsA.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical guidelines to assess disease severity in patients with psoriatic arthritis
  • Integrate patient workup to assist in diagnosis of psoriatic arthritis
  • Apply current guidelines into treatment to improve outcomes of patients with psoriatic arthritis

Topics covered include:

  • Diagnosis
  • Assessing Disease Activity
  • Treatment
 

Faculty

  • Vinod Chandran
    MBBS, MD, DM, PhD

Credit Information

  • Release Date:
    January 03, 2017
  • Expiration Date:
    January 02, 2018
  • Physicians:
    maximum of 0.5 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Vinod Chandran, MBBS, MD, DM, PhD


Assistant Professor
Consultant Rheumatologist
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Toronto, Canada

Vinod Chandran, MBBS, MD, DM, PhD, has disclosed that he has received consulting fees from Abbott/AbbVie, Amgen, Celgene, Janssen, and Pfizer; fees for non-CME/CE services from Abbott/AbbVie, Amgen, Janssen, and Pfizer; and funds for research support from Abbott/AbbVie.
 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests.
 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.
 

Alyce Kuklinski, NP, RN


General Manager, Virology & Other Therapeutic Specialties

Alyce Kuklinski, NP, RN, has nothing to disclose with regard to commercial interests.
 

Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

 

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the medical management of patients with rheumatologic conditions.


Goal

The goal of this activity is to improve the knowledge and competence of physicians and other healthcare providers for the prevention, diagnosis, and treatment of patients with rheumatologic conditions.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply clinical guidelines to assess disease severity in patients with psoriatic arthritis
  • Integrate patient workup to assist in diagnosis of psoriatic arthritis
  • Apply current guidelines into treatment to improve outcomes of patients with psoriatic arthritis
 

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Clinical Care Options, LLC. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Boston University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Genentech, and Lilly USA, LLC..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 03, 2017, through January 02, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • The End of Winter or a False Spring? Introduction of Biosimilars in a Rheumatology Practice

    William F. C. Rigby MD - 6/12/2017    
    What does the availability of biosimilar products mean in your approach to rheumatologic conditions?
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017    2 comments / Last Comment: 4/24/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Post-ACR Update: New Developments That Could Affect Treatment of Psoriatic Arthritis

    Vinod Chandran MBBS, MD, DM, PhD - 2/6/2015    1 comment / Last Comment: 3/18/2015
    The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?
  • Targeting IL-17 in Psoriatic Arthritis: Key Data From the 2016 ACR Meeting

    Arthur Kavanaugh MD - 2/1/2017    1 comment / Last Comment: 2/2/2017
    The 2016 American College of Rheumatology annual meeting gave us promising data on agents targeting IL-17 in psoriatic arthritis. Here’s my take on select abstracts.